AbbVie (ABBV) to Acquire Apogee Therapeutics

AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes asthma and atopic dermatitis. Management stated that the acquisition complements the company's present immunology portfolio and bolsters its clinical presence in the respiratory space.

The company further stated that, according to the terms of the transaction, AbbVie Inc. (NYSE:ABBV) will acquire all outstanding shares of Apogee for $135.11 per share in cash, with the transaction valuing Apogee at a total equity value of approximately $10.9 billion. The transaction was unanimously approved by the boards of directors of both companies, and management expects the transaction to close in fiscal Q3 2026. This is subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and se

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/abbvie-abbv-acquire-apogee-therapeutics-192139000.html)